From April 1, 2024 to April 3, 2024, the company has repurchased 6,479,843 shares, representing 0.8% for CNY 154.55 million. With this, the company has completed the repurchase of 24,242,904 shares, representing 3% for CNY 500 million under the buyback announced on July 17, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
28.65 CNY | +4.18% | +6.90% | +28.88% |
May. 24 | Jafron Biomedical Co.,Ltd. Announces Final Dividend on A Shares for 2023, Payable on 31 May 2024 | CI |
Apr. 26 | Jafron Biomedical Co.,Ltd. Proposes Final Dividend for the Year 2023 | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+28.88% | 2.93B | |
-5.35% | 179B | |
-5.23% | 98.81B | |
-7.75% | 64.7B | |
+17.84% | 44.56B | |
-9.21% | 44.06B | |
+8.09% | 43.8B | |
+11.97% | 28.28B | |
+20.27% | 25.89B | |
-5.34% | 23.41B |
- Stock Market
- Equities
- 300529 Stock
- News Jafron Biomedical Co.,Ltd.
- Tranche Update on Jafron Biomedical Co.,Ltd.'s Equity Buyback Plan announced on July 17, 2023.